TRIANA Biomedicines
PrivateLast Round
Series B
Dec 3, 2025
Est. Valuation
$258M
Total Funding Raised
$350M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
TRIANA Biomedicines is a biotechnology company that discovers and develops molecular glue therapeutics to target and degrade disease-causing proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TRIANA Biomedicines Comparables
Compare TRIANA Biomedicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 85% | |
| SEED Therapeutics | 85% | |
| Neomorph | 85% |
TRIANA Biomedicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 3, 2025 | ||||
| Series B | Dec 3, 2024 | ||||
| Series A | Apr 6, 2022 |
Key People
Founding team and executive leadership
TRIANA Biomedicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series B, Series A |
| RA Capital Management | Series B, Seed, Series A |
| Finchley Healthcare Ventures | Series B |
| Invus Opportunities | Series B |
| Logos Capital | Series A |
| Accomplice | Series B |
| Citadel | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors increased 149% MoM, reaching 6.2K.
- Apr 15, 2026
Presenting candidate TRI-611 at AACR Annual Meeting 2026.
TRIANA Biomedicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TRIANA Biomedicines's valuation, stock price, and market status.
Is TRIANA Biomedicines a public or private company?
TRIANA Biomedicines is a private company.
What is the current stock price of TRIANA Biomedicines?
TRIANA Biomedicines is a private company, so its shares have no public market price. Caplight tracks TRIANA Biomedicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TRIANA Biomedicines worth (valuation)?
TRIANA Biomedicines's valuation is estimated at $258.0M based on funding round data.
Can I buy TRIANA Biomedicines stock?
TRIANA Biomedicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TRIANA Biomedicines's last funding round?
TRIANA Biomedicines's most recent funding round was Series B on December 3, 2025.
Who are the main investors in TRIANA Biomedicines?
Key investors in TRIANA Biomedicines include RA Capital Management, Bessemer Venture Partners, Atlas Venture, Lightspeed Venture Partners, Ascenta Capital.
Will TRIANA Biomedicines IPO soon?
No public IPO plans have been announced for TRIANA Biomedicines.
How can I track TRIANA Biomedicines secondary market activity?
Caplight tracks bids, offers, and trades in TRIANA Biomedicines's shares on secondary markets.